Ninke E A Wellerdieck1,2, Peter Wessels1,2, Maartje Los3, Gabe S Sonke4, Ellen Tromp5, Dieta Brandsma6. 1. Department of Neuro-Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands. 2. Department of Neurology, St Antonius Hospital, Utrecht/Nieuwegein, The Netherlands. 3. Department of Internal Medicine, St Antonius Hospital, Utrecht/Nieuwegein, The Netherlands. 4. Department of Medical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands. 5. Department of Clinical Epidemiology, St Antonius Hospital, Utrecht, The Netherlands. 6. Department of Neuro-Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands. d.brandsma@nki.nl.
Abstract
PURPOSE: As survival of patients with central nervous system (CNS) metastases from breast cancer is poor and incidence rates are increasing, there is a growing need for better treatment strategies. In the current study, the efficacy of local and systemic therapies was analyzed in breast cancer patients with CNS metastases. METHODS: Medical records from breast cancer patients with brain and/or leptomeningeal metastases (LM) treated at a tertiary referral center and a teaching hospital between 2010 and 2020 were retrospectively studied. Main outcomes of interest were overall survival (OS) and CNS progression free survival. Analyses were performed among patients with brain metastases (BM) and patients with LM, for the different systemic and local therapies for CNS metastases, and for subgroups based on breast cancer subtypes. RESULTS: We identified 155 patients, 97 with BM and 58 with LM. Median OS was 15.9 months for patients with BM and 1.5 months for patients with LM. Median OS was significantly longer for HER2-positive patients with BM (22.8 months) vs triple negative (8.4 months) and hormone receptor positive/HER2-negative (5.9 months) (P < 0.001). Patients with BM receiving both local and systemic therapy also had a longer median OS (21.8 months), compared to the other three subgroups (local therapy only: 9.9 months, systemic therapy only: 4.3 months, no therapy: 0.5 months, P < 0.001). No significant difference in OS was observed between different systemic treatment regimens. CONCLUSION: Breast cancer patients with BM show longest median OS when the subtype is HER2-positive and when they are treated with both local and systemic therapy.
PURPOSE: As survival of patients with central nervous system (CNS) metastases from breast cancer is poor and incidence rates are increasing, there is a growing need for better treatment strategies. In the current study, the efficacy of local and systemic therapies was analyzed in breast cancer patients with CNS metastases. METHODS: Medical records from breast cancer patients with brain and/or leptomeningeal metastases (LM) treated at a tertiary referral center and a teaching hospital between 2010 and 2020 were retrospectively studied. Main outcomes of interest were overall survival (OS) and CNS progression free survival. Analyses were performed among patients with brain metastases (BM) and patients with LM, for the different systemic and local therapies for CNS metastases, and for subgroups based on breast cancer subtypes. RESULTS: We identified 155 patients, 97 with BM and 58 with LM. Median OS was 15.9 months for patients with BM and 1.5 months for patients with LM. Median OS was significantly longer for HER2-positive patients with BM (22.8 months) vs triple negative (8.4 months) and hormone receptor positive/HER2-negative (5.9 months) (P < 0.001). Patients with BM receiving both local and systemic therapy also had a longer median OS (21.8 months), compared to the other three subgroups (local therapy only: 9.9 months, systemic therapy only: 4.3 months, no therapy: 0.5 months, P < 0.001). No significant difference in OS was observed between different systemic treatment regimens. CONCLUSION: Breast cancer patients with BM show longest median OS when the subtype is HER2-positive and when they are treated with both local and systemic therapy.
Authors: Bernhard C Pestalozzi; Eileen Holmes; Evandro de Azambuja; Otto Metzger-Filho; Laurence Hogge; Matt Scullion; István Láng; Andrew Wardley; Mikhail Lichinitser; Roberto I Lopez Sanchez; Volkmar Müller; David Dodwell; Richard D Gelber; Martine J Piccart-Gebhart; David Cameron Journal: Lancet Oncol Date: 2013-02-13 Impact factor: 41.316
Authors: Adam S Komorowski; Ellen Warner; Helen J MacKay; Arjun Sahgal; Kathleen I Pritchard; Katarzyna J Jerzak Journal: Clin Breast Cancer Date: 2019-07-11 Impact factor: 3.225
Authors: Jonathan W Rick; Maryam Shahin; Ankush Chandra; Cecilia Dalle Ore; John K Yue; Alan Nguyen; Garima Yagnik; Soumya Sagar; Saman Arfaie; Manish K Aghi Journal: Crit Rev Oncol Hematol Date: 2019-07-22 Impact factor: 6.312
Authors: Shaan Dudani; Sasha Mazzarello; John Hilton; Brian Hutton; Lisa Vandermeer; Ricardo Fernandes; Mohammed F K Ibrahim; Stephanie Smith; Habeeb Majeed; Khalid Al-Baimani; Jean-Michel Caudrelier; Risa Shorr; Mark Clemons Journal: Clin Breast Cancer Date: 2016-07-28 Impact factor: 3.225
Authors: Daniel P Cahill; Ryan J Sullivan; Priscilla K Brastianos; Eudocia Quant Lee; Justine V Cohen; Sara M Tolaney; Nancy U Lin; Nancy Wang; Ugonma Chukwueke; Michael D White; Naema Nayyar; Albert Kim; Christopher Alvarez-Breckenridge; Ian Krop; Maura Keeley Mahar; Mia S Bertalan; Brian Shaw; Joana L Mora; Nathaniel Goss; Megha Subramanian; Lakshmi Nayak; Jorg Dietrich; Deborah A Forst; Brian V Nahed; Tracy T Batchelor; Helen A Shih; Elizabeth R Gerstner; Beverly Moy; Donald Lawrence; Anita Giobbie-Hurder; Scott L Carter; Kevin Oh Journal: Nat Med Date: 2020-06-02 Impact factor: 53.440